Sei Investments Co. Has $225.48 Million Stake in argenx SE (NASDAQ:ARGX)

Sei Investments Co. decreased its stake in shares of argenx SE (NASDAQ:ARGX) by 3.7% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 366,620 shares of the company’s stock after selling 14,075 shares during the period. Sei Investments Co.’s holdings in argenx were worth $225,475,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Steward Partners Investment Advisory LLC grew its position in argenx by 5.6% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock valued at $234,000 after purchasing an additional 20 shares during the period. SG Americas Securities LLC grew its position in argenx by 6.2% in the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after purchasing an additional 21 shares during the period. Farther Finance Advisors LLC grew its position in argenx by 38.2% in the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock valued at $47,000 after purchasing an additional 21 shares during the period. Dynasty Wealth Management LLC grew its position in argenx by 3.4% in the 4th quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock valued at $416,000 after purchasing an additional 22 shares during the period. Finally, Choreo LLC grew its position in argenx by 4.4% in the 4th quarter. Choreo LLC now owns 551 shares of the company’s stock valued at $342,000 after purchasing an additional 23 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Stock Performance

Shares of argenx stock opened at $615.02 on Friday. argenx SE has a 52-week low of $352.77 and a 52-week high of $678.21. The stock’s 50-day simple moving average is $634.69 and its 200 day simple moving average is $599.15. The stock has a market capitalization of $37.37 billion, a P/E ratio of -698.89 and a beta of 0.59.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analysts’ expectations of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Equities research analysts forecast that argenx SE will post 3.13 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. William Blair reaffirmed an “outperform” rating on shares of argenx in a report on Friday, February 28th. Piper Sandler lifted their price objective on shares of argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a report on Tuesday, January 7th. Deutsche Bank Aktiengesellschaft raised shares of argenx from a “sell” rating to a “hold” rating in a report on Wednesday, March 12th. Oppenheimer lifted their price objective on shares of argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Finally, Truist Financial reaffirmed a “buy” rating and set a $700.00 price objective (up from $660.00) on shares of argenx in a report on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $687.00.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.